Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lara Arias Garcia"'
Autor:
Beatriz Sicilia Aladrén, Yago González-Lama, María García-Alvarado, Mónica Sierra, Jésus Andrés Barrio, Vanesa Prieto Vicente, Luis Hernández, Benito Velayos, Lara Arias Garcia, Lucia Relea, Patricia Suarez, Ramón Atienza, Mónica Vásquez, Luis Fernández-Salazar, Fernando Muñoz
Publikováno v:
Endoscopy International Open, Vol 07, Iss 06, Pp E743-E750 (2019)
Background and study aims Chromoendoscopy with targeted biopsy is the technique of choice for colorectal cancer screening in longstanding inflammatory bowel disease. We aimed to analyze results of a chromoendoscopy screening program and to assess the
Externí odkaz:
https://doaj.org/article/9d9b2a277e334d6686bc791bb8c2893b
Autor:
Celia Gómez-Labrador, Elena Ricart, Marisa Iborra, Eva Iglesias, María Dolores Martín-Arranz, Luisa de Castro, Ruth De Francisco, Francisco Javier García-Alonso, Ana Sanahuja, Carla J. Gargallo-Puyuelo, Francisco Mesonero, María José Casanova, Míriam Mañosa, Montserrat Rivero, Marta Calvo, Mónica Sierra-Ausin, Carlos González-Muñoza, Xavier Calvet, Santiago García-López, Jordi Guardiola, Lara Arias García, Lucía Márquez-Mosquera, Ana Gutiérrez, Yamile Zabana, Mercè Navarro-Llavat, Rufo Lorente Poyatos, Marta Piqueras, Leyanira Torrealba, Fernando Bermejo, Ángel Ponferrada-Díaz, José L. Pérez-Calle, Manuel Barreiro-de Acosta, Coral Tejido, José Luis Cabriada, Ignacio Marín-Jiménez, Óscar Roncero, Yolanda Ber, Luis Fernández-Salazar, Blau Camps Aler, Alfredo J. Lucendo, Jordina Llaó, Luis Bujanda, Carmen Muñoz Villafranca, Eugeni Domènech, María Chaparro, Javier P. Gisbert
Publikováno v:
Pharmaceutics, Vol 16, Iss 5, p 629 (2024)
Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEI
Externí odkaz:
https://doaj.org/article/07a5bfcf65344f8daf0648e08c7a639c
Autor:
María Chaparro, Iria Baston-Rey, Estela Fernández Salgado, Javier González García, Laura Ramos, María Teresa Diz-Lois Palomares, Federico Argüelles-Arias, Eva Iglesias Flores, Mercedes Cabello, Saioa Rubio Iturria, Andrea Núñez Ortiz, Mara Charro, Daniel Ginard, Carmen Dueñas Sadornil, Olga Merino Ochoa, David Busquets, Eduardo Iyo, Ana Gutiérrez Casbas, Patricia Ramírez de la Piscina, Marta Maia Boscá-Watts, Maite Arroyo, María José García, Esther Hinojosa, Jordi Gordillo, Pilar Martínez Montiel, Benito Velayos Jiménez, Cristina Quílez Ivorra, Juan María Vázquez Morón, José María Huguet, Yago González-Lama, Ana Isabel Muñagorri Santos, Víctor Manuel Amo, María Dolores Martín Arranz, Fernando Bermejo, Jesús Martínez Cadilla, Cristina Rubín de Célix, Paola Fradejas Salazar, Antonio López San Román, Nuria Jiménez, Santiago García-López, Anna Figuerola, Itxaso Jiménez, Francisco José Martínez Cerezo, Carlos Taxonera, Pilar Varela, Ruth de Francisco, David Monfort, Gema Molina Arriero, Alejandro Hernández-Camba, Francisco Javier García Alonso, Manuel Van Domselaar, Ramón Pajares-Villarroya, Alejandro Núñez, Francisco Rodríguez Moranta, Ignacio Marín-Jiménez, Virginia Robles Alonso, María del Mar Martín Rodríguez, Patricia Camo-Monterde, Iván García Tercero, Mercedes Navarro-Llavat, Lara Arias García, Daniel Hervías Cruz, Sebastian Kloss, Alun Passey, Cynthia Novella, Eugenia Vispo, Manuel Barreiro-de Acosta, Javier P. Gisbert
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 15, p 4518 (2022)
Ustekinumab has shown efficacy in Crohn’s Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position this drug in the therapeutic paradigm of CD and generate hypotheses for future tr
Externí odkaz:
https://doaj.org/article/bbc704ff26a449c5831cf6c241ff6dbe